Please assess the completion status of the following clinical trial:

Trial Title: Dose-Responsive Effect of Polydextrose on Whole Gut Transit Time

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 70 years~* Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and overweight)~* Meets the Rome III criteria for functional constipation as follows: (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis):~Must meet 2 or more of the following criteria:~* Straining during at least 25% of defecations~* Lumpy or hard stools in at least 25% of defecations~* Sensation of incomplete evacuation for at least 25% of defecations~* Sensation of anorectal obstruction/blockage for at least 25% of defecations~* Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)~* Fewer than three defecations per week~  * Loose stools are rarely present without the use of laxatives~ * Insufficient criteria for irritable bowel syndrome~ * Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects~ * Consent to the study and willing to comply with study product and methods~ * Willingness to maintain a stable diet throughout the study~ * Consistent use and dose of chronic medication, if any, in the past 30 days~Exclusion Criteria:~* Major gastrointestinal complication (e.g. Crohns disease, colitis, celiac disease)~* Febrile diverticulitis within 1 year of screening~* Pelvic floor dysfunction~* Prior abdominal surgery that in the opinion of the investigator may present a risk for the subject or confound study results~* Prior abdominal surgery of the following type: gastric bypass, lap band, colectomy, removal of gall bladder~* Clinically significant underlying systemic illness that may preclude the subjects ability to complete the trial or that may confound the study outcomes~* Any clinically relevant abnormalities in the physical examination or in laboratory variables before entry into the study~* Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening~* Laxative, fiber supplement, or other constipation medication (e.g. prokinetic drugs) use within 2 weeks of screening~* Antibiotic use within 1 month of enrollment~* Regular use of any drug or dietary supplement known to cause constipation (e.g. iron, opioids, sucralfate, misoprostol, 5-HT#- antagonists, antacids with magnesium or aluminum, or diarrhea medication)~* Anticipated major dietary or exercise changes during the study period~* Known allergies to any substance in the study product~* Pregnant or lactating female, or pregnancy planned during study period~* Eating disorder~* History of alcohol, drug, or medication abuse~* Participation in another study with any investigational product within 3 months of screening~* Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Polydextrose, low dose (Type: ACTIVE_COMPARATOR): Polydextrose, low dose
- Polydextrose, medium dose (Type: ACTIVE_COMPARATOR): Polydextrose, medium dose
- Polydextrose, high dose (Type: ACTIVE_COMPARATOR): Polydextrose, high dose
- Placebo powder (Type: PLACEBO_COMPARATOR): Placebo powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues